Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.

Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, Saito T, Laé M, Fisher DE, Ladanyi M.

Cancer Res. 2007 Feb 1;67(3):919-29.

2.

The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25.

Ladanyi M, Lui MY, Antonescu CR, Krause-Boehm A, Meindl A, Argani P, Healey JH, Ueda T, Yoshikawa H, Meloni-Ehrig A, Sorensen PH, Mertens F, Mandahl N, van den Berghe H, Sciot R, Dal Cin P, Bridge J.

Oncogene. 2001 Jan 4;20(1):48-57.

3.

Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein.

Kobos R, Nagai M, Tsuda M, Merl MY, Saito T, Laé M, Mo Q, Olshen A, Lianoglou S, Leslie C, Ostrovnaya I, Antczak C, Djaballah H, Ladanyi M.

J Pathol. 2013 Apr;229(5):743-754. doi: 10.1002/path.4158. Epub 2013 Mar 5.

4.

Alveolar soft part sarcoma: a bimarker diagnostic strategy using TFE3 immunoassay and ASPL-TFE3 fusion transcripts in paraffin-embedded tumor tissues.

Pang LJ, Chang B, Zou H, Qi Y, Jiang JF, Li HA, Hu WH, Chen YZ, Liu CX, Zhang WJ, Li F.

Diagn Mol Pathol. 2008 Dec;17(4):245-52. doi: 10.1097/PDM.0b013e31815d68d7.

PMID:
18382356
5.

Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma.

Vistica DT, Krosky PM, Kenney S, Raffeld M, Shoemaker RH.

J Pediatr Hematol Oncol. 2008 Jan;30(1):46-52. doi: 10.1097/MPH.0b013e31815d1d6f.

PMID:
18176180
6.

Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay.

Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M.

Am J Surg Pathol. 2003 Jun;27(6):750-61.

PMID:
12766578
7.

Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.

Martignoni G, Pea M, Gobbo S, Brunelli M, Bonetti F, Segala D, Pan CC, Netto G, Doglioni C, Hes O, Argani P, Chilosi M.

Mod Pathol. 2009 Aug;22(8):1016-22. doi: 10.1038/modpathol.2009.58. Epub 2009 Apr 24.

8.

Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.

Reis H, Hager T, Wohlschlaeger J, Bauer S, Katenkamp K, Katenkamp D, Baba HA.

Hum Pathol. 2013 Oct;44(10):2266-74. doi: 10.1016/j.humpath.2013.04.018. Epub 2013 Jul 17.

PMID:
23871289
9.

Detection of the ASPSCR1-TFE3 gene fusion in paraffin-embedded alveolar soft part sarcomas.

Aulmann S, Longerich T, Schirmacher P, Mechtersheimer G, Penzel R.

Histopathology. 2007 Jun;50(7):881-6.

PMID:
17543078
10.

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JJ, Cherrington JM, Mendel DB.

Cancer Res. 2003 Nov 1;63(21):7345-55.

11.

Inhibition of the met receptor in mesothelioma.

Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, Jänne PA.

Clin Cancer Res. 2005 Nov 15;11(22):8122-30.

13.

Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.

Argani P, Antonescu CR, Illei PB, Lui MY, Timmons CF, Newbury R, Reuter VE, Garvin AJ, Perez-Atayde AR, Fletcher JA, Beckwith JB, Bridge JA, Ladanyi M.

Am J Pathol. 2001 Jul;159(1):179-92.

14.

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R.

Cancer Res. 2005 Feb 15;65(4):1479-88.

15.

ASPL-TFE3 Oncoprotein Regulates Cell Cycle Progression and Induces Cellular Senescence by Up-Regulating p21.

Ishiguro N, Yoshida H.

Neoplasia. 2016 Oct;18(10):626-635. doi: 10.1016/j.neo.2016.08.001. Epub 2016 Sep 24.

16.

Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.

Martignoni G, Gobbo S, Camparo P, Brunelli M, Munari E, Segala D, Pea M, Bonetti F, Illei PB, Netto GJ, Ladanyi M, Chilosi M, Argani P.

Mod Pathol. 2011 Oct;24(10):1313-9. doi: 10.1038/modpathol.2011.93. Epub 2011 May 20.

17.

A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23).

Argani P, Lui MY, Couturier J, Bouvier R, Fournet JC, Ladanyi M.

Oncogene. 2003 Aug 14;22(34):5374-8.

PMID:
12917640
18.

A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.

Hov H, Holt RU, Rø TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Børset M.

Clin Cancer Res. 2004 Oct 1;10(19):6686-94.

19.

Adult-onset renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusion with smooth muscle stroma and abnormal vessels.

Kuroda N, Tamura M, Tanaka Y, Hes O, Michal M, Inoue K, Ohara M, Mizuno K, Lee GH.

Pathol Int. 2009 Jul;59(7):486-91. doi: 10.1111/j.1440-1827.2009.02398.x.

PMID:
19563413
20.

Renal carcinoma-associated transcription factors TFE3 and TFEB are leukemia inhibitory factor-responsive transcription activators of E-cadherin.

Huan C, Sashital D, Hailemariam T, Kelly ML, Roman CA.

J Biol Chem. 2005 Aug 26;280(34):30225-35. Epub 2005 Jun 30.

Supplemental Content

Support Center